Other equities analysts have also recently issued research reports about the company. Cowen reaffirmed a “buy” rating on shares of Gritstone Oncology in a report on Monday, May 13th. Robert W. Baird began coverage on Gritstone Oncology in a report on Thursday, July 25th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Zacks Investment Research cut Gritstone Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, July 17th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.00.
GRTS traded down $1.15 on Thursday, reaching $9.51. The stock had a trading volume of 138,018 shares, compared to its average volume of 124,148. Gritstone Oncology has a fifty-two week low of $8.75 and a fifty-two week high of $32.90. The firm’s 50-day moving average price is $10.68. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.57 and a quick ratio of 9.57. The stock has a market cap of $375.05 million and a P/E ratio of -1.31.
Several hedge funds have recently modified their holdings of GRTS. Citigroup Inc. acquired a new stake in shares of Gritstone Oncology in the fourth quarter valued at about $28,000. American International Group Inc. acquired a new stake in shares of Gritstone Oncology in the fourth quarter valued at about $70,000. Marshall Wace North America L.P. acquired a new stake in shares of Gritstone Oncology in the first quarter valued at about $84,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Gritstone Oncology in the fourth quarter valued at about $157,000. Finally, Stanley Laman Group Ltd. acquired a new stake in shares of Gritstone Oncology in the second quarter valued at about $313,000. 57.52% of the stock is owned by institutional investors.
About Gritstone Oncology
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Featured Story: How are the companies in the S&P 500 selected?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.